These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9030825)

  • 41. Use of quinapril in the elderly patient.
    Schnaper HW
    Am J Hypertens; 1990 Nov; 3(11):278S-282S. PubMed ID: 2261146
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insulin-like growth factor-1 and cardiac mass in essential hypertension: comparative effects of captopril, lisinopril and quinapril.
    Díez J; Laviades C
    J Hypertens Suppl; 1994 Jul; 12(4):S31-6. PubMed ID: 7965272
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Visceral fat in hypertension: influence on insulin resistance and beta-cell function.
    Sironi AM; Gastaldelli A; Mari A; Ciociaro D; Positano V; Buzzigoli E; Ghione S; Turchi S; Lombardi M; Ferrannini E
    Hypertension; 2004 Aug; 44(2):127-33. PubMed ID: 15262911
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interaction between glucose metabolism and endogenous insulin release in hypertension.
    Natalucci S; Boemi M; Fumelli D; Fumelli P; Burattini R
    Metabolism; 2002 Mar; 51(3):297-303. PubMed ID: 11887163
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients.
    Fogari R; Derosa G; Zoppi A; Lazzari P; Corradi L; Preti P; Mugellini A
    Intern Med; 2008; 47(5):361-6. PubMed ID: 18310964
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Visceral adipose tissue impairs insulin secretion and insulin sensitivity but not energy expenditure in obesity.
    Macor C; Ruggeri A; Mazzonetto P; Federspil G; Cobelli C; Vettor R
    Metabolism; 1997 Feb; 46(2):123-9. PubMed ID: 9030815
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Secretory dysfunction of vascular endothelium limits the effect of angiotensin converting enzyme inhibitor quinapril on aggregation of erythrocytes in experimental hypertension.
    Korbut RA; Madej J; Adamek-Guzik T; Korbut R
    J Physiol Pharmacol; 2003 Sep; 54(3):397-408. PubMed ID: 14566078
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The treatment of moderate to severe hypertension with ACE inhibitors.
    Goldstein RJ
    J Cardiovasc Pharmacol; 1990; 15 Suppl 2():S29-35. PubMed ID: 1691404
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The effect of cilazapril and prazosin on insulin sensitivity in patients with essential hypertension].
    Cirić J; Zarković M; Trbojević B; Tasić N; Nesović M
    Med Pregl; 1995; 48(9-10):326-8. PubMed ID: 8628189
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quinapril versus enalapril in the treatment of mild-to-moderate essential hypertension.
    Sánchez S; Luna A; Orozco R; Velasco G
    Clin Ther; 1991; 13(5):651-5. PubMed ID: 1799922
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The safety profile of quinapril: is there a difference among ACE inhibitors?
    Canter D; Frank GJ; Knapp LE; McLain RW
    Clin Cardiol; 1990 Jun; 13(6 Suppl 7):VII39-42. PubMed ID: 2189620
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Angiotensin-converting enzyme inhibition by quinapril blocks the albuminuric effect of atrial natriuretic peptide in Type 1 diabetes and microalbuminuria.
    McKenna K; Smith D; Barrett P; Glenn A; Kesson CM; Connell J; Thompson CJ
    Diabet Med; 2000 Mar; 17(3):219-24. PubMed ID: 10784227
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin.
    Hu K; Gaudron P; Anders HJ; Weidemann F; Turschner O; Nahrendorf M; Ertl G
    Cardiovasc Res; 1998 Aug; 39(2):401-12. PubMed ID: 9798525
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Insulin resistance in essential hypertensive patients with impaired glucose tolerance.
    Sekiya M; Yamasaki Y; Tsujino T; Shiba Y; Kubota M; Kawamori R; Kamada T
    Diabetes Res Clin Pract; 1995 Jul; 29(1):49-56. PubMed ID: 8593759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.
    Plosker GL; Sorkin EM
    Drugs; 1994 Aug; 48(2):227-52. PubMed ID: 7527326
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.
    Culy CR; Jarvis B
    Drugs; 2002; 62(2):339-85. PubMed ID: 11817979
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduced beta-cell compensation to the insulin resistance associated with obesity in members of caucasian familial type 2 diabetic kindreds.
    Elbein SC; Wegner K; Kahn SE
    Diabetes Care; 2000 Feb; 23(2):221-7. PubMed ID: 10868835
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overview of the clinical development of quinapril.
    Frank GJ
    Clin Cardiol; 1990 Jun; 13(6 Suppl 7):VII13-8. PubMed ID: 2189616
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Additive effects of diltiazem and lisinopril in the treatment of elderly patients with mild-to-moderate hypertension.
    Chan P; Lin CN; Tomlinson B; Lin TH; Lee YS
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):743-9. PubMed ID: 9234828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.